Voyager Therapeutics to Present at the Canaccord Genuity Growth Conference

CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that Chief Scientific Officer Todd Carter, Ph.D., and Chief Financial Officer Peter Pfreundschuh will participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference on Thursday, August 10, 2023, at 10:30 a.m. ET.

A webcast of the presentation may be accessed from the Investors section of Voyager’s website at ir.voyagertherapeutics.com. A replay of the webcast will be archived on the Company's website for at least 30 days.

About Voyager Therapeutics
Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The potential of both disciplines has been constrained by delivery challenges; Voyager is leveraging cutting-edge expertise in capsid discovery and deep neuropharmacology capabilities to address these constraints. Voyager’s TRACER AAV capsid discovery platform has generated novel capsids with high target delivery and blood-brain barrier penetration at low doses, potentially addressing the narrow therapeutic window associated with conventional gene therapy delivery vectors. This platform is fueling alliances with Pfizer Inc., Novartis Pharma AG, Neurocrine Biosciences, Inc. and Sangamo Therapeutics, Inc., as well as multiple programs in Voyager’s own pipeline. Voyager’s pipeline includes wholly-owned and collaborative preclinical programs in Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other diseases of the central nervous system, with a focus on validated targets and biomarkers to enable a path to rapid potential proof-of-biology. For more information, visit www.voyagertherapeutics.com.

Voyager Therapeutics^® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc. 

Contacts
Investors
Investors@vygr.com

Media
Peg Rusconi
prusconi@vergescientific.com